Latin America Leukemia Therapeutics Market Report

Latin America Leukemia Therapeutics Market Size

The Latin America leukemia therapeutics market size was valued at USD 0.91 billion in 2025 and is anticipated to reach USD 1.01 billion in 2026 from USD 2.28 billion by 2034, growing at a CAGR of 10.7% during the forecast period from 2026 to 2034.

Leukemia is a type of blood cancer resulting in the abnormal production of blood cells, generally white blood cells. There are several types of leukemia that appear suddenly and progress rapidly over days to weeks. Others are less apparent and progress slowly over months to years. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.

The market in Latin America for Leukemia Therapeutics is driving mainly due to factors like increasing geriatric population base and high prevalence of leukemia, along with increasing awareness in people regarding new treatments and drugs which is being made possible with recent breakthroughs.

But the market growth can dip due to the extremely high cost of drugs and therapies.

By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.

Due to rising awareness of healthcare among the population in developing nations of this region, there is quite an increase in the penetration of companies into this segment, as well as the regional market in Latin America.

KEY MARKET PLAYERS

Prominent companies leading in the Latin America Leukemia Therapeutics market include

• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline Pharmaceuticals Limited
• Novartis International AG
• Bristol-Myers Squibb
• Eisai Co. Ltd.
• Biogen Idec
• ERYtech Pharma
• Celgene Corporation
• Genmab A/S
• Cephalon Inc.
• Clavis Pharma
• Pfizer Inc.

MARKET SEGMENTATION

This research report on the LATAM Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories.

By Disease Condition

• Chronic Lymphatic Leukemia
• Acute Lymphatic Leukemia
• Chronic Myeloid Leukemia
• Acute Myeloid Leukemia

By Diagnosis

• CT scan
• Biopsy
• MRI

By Treatments

• Chemotherapy
• Radiation therapy
• Immunotherapy
• Surgery
• Targeted Therapy
• Bone marrow transplant
• Stem Cell Therapy

By Drugs

• Gleevec
• Sapacitabine
• GA101
• Vasaroxine
• Tosedosat

By Country

• Brazil
• Mexico
• Argentina
• Chile
• Rest of Latin America